#Biotechnology

Articles (30)

• 🇺🇸 Flight Path Data Shows How Mosquitoes Target Humans — 11/04/2026 [USA]

  Scientists have quantified what draws mosquitoes to people—which could help make better, life-saving bug traps.

  Related: #Public Health, #Entomology
• 🇺🇸 Form 13D/A Adicet Bio For: 10 April — 11/04/2026 [USA] Related: #Corporate Governance, #Financial Regulation
• 🇺🇸 Apogee Therapeutics CEO Henderson sells $1.65 million in stock — 11/04/2026 [USA] Related: #Corporate Governance, #Financial Markets
• 🇺🇸 Form DEF 14A Apogee Therapeutics Inc For: 10 April — 10/04/2026 [USA] Related: #Corporate Governance, #Regulatory Compliance
• 🇺🇸 Form PRE 14A SOLID BIOSCIENCES INC. For: 10 April — 10/04/2026 [USA] Related: #Corporate Governance, #Financial Regulation
• 🇺🇸 Form DEF 14A KURA ONCOLOGY For: 10 April — 10/04/2026 [USA] Related: #Corporate Governance, #Regulatory Compliance
• 🇺🇸 Robins, Adaptive Biotechnologies CSO, sells $148,500 in stock — 10/04/2026 [USA] Related: #Corporate Governance, #Financial Markets
• 🇺🇸 BiomX stockholders approve 2026 equity incentive plan at special meeting — 10/04/2026 [USA] Related: #Corporate Governance, #Executive Compensation
• 🇺🇸 Rothblatt, United Therapeutics CEO, sells $5.5 million in UTHR stock — 10/04/2026 [USA] Related: #Executive Trading, #Corporate Governance
• 🇺🇸 United Therapeutics CFO Edgemond sells $5.77 million in UTHR stock — 10/04/2026 [USA] Related: #Corporate Finance, #Stock Markets
• 🇺🇸 Ginkgo Bioworks director Shetty sells $175k in shares — 10/04/2026 [USA] Related: #Corporate Governance, #Financial Markets
• 🇺🇸 Ginkgo Bioworks CEO sells $1.37 million in shares — 10/04/2026 [USA] Related: #Corporate Governance, #Financial Markets
• 🇺🇸 Ginkgo Bioworks 10% owner Canton sells $175k in DNA stock — 10/04/2026 [USA] Related: #Finance, #Markets
• 🇺🇸 Pelthos Therapeutics names John Gay as chief financial officer — 10/04/2026 [USA] Related: #Corporate Leadership, #Financial Strategy
• 🇺🇸 AIM ImmunoTech amends equity distribution agreement to remove share sale limit — 10/04/2026 [USA] Related: #Corporate Finance, #Capital Markets
• 🇺🇸 Cantor Fitzgerald downgrades Replimune stock rating after second FDA rejection — 10/04/2026 [USA] Related: #Financial Markets, #Regulatory Affairs
• 🇺🇸 Form 144 Ginkgo Bioworks Holdings For: 10 April — 10/04/2026 [USA] Related: #Financial Regulation, #Capital Markets
• 🇺🇸 Jefferies raises Zentalis stock price target on ovarian cancer trial data — 10/04/2026 [USA] Related: #Finance, #Healthcare
• 🇺🇸 Jefferies reiterates Iovance Biotherapeutics stock rating at buy — 10/04/2026 [USA] Related: #Financial Analysis, #Investment Ratings
• 🇺🇸 Form 6K Cardiol Therapeutics Inc. For: 10 April — 10/04/2026 [USA] Related: #Corporate Compliance, #Financial Reporting
• 🇺🇸 Verastem stock maintains Buy rating at BTIG on durable trial data — 10/04/2026 [USA] Related: #Financial Analysis, #Clinical Trials
• 🇺🇸 Mizuho raises Alkermes stock price target to $53 on drug confidence — 10/04/2026 [USA] Related: #Finance, #Healthcare
• 🇺🇸 H.C. Wainwright reiterates Buy on Telix stock, $20 target on FDA review — 10/04/2026 [USA] Related: #Financial Analysis, #Healthcare Regulation
• 🇺🇸 H.C. Wainwright reiterates Zentalis stock rating on pivotal dose selection — 10/04/2026 [USA] Related: #Financial Analysis, #Pharmaceutical Development
• 🇺🇸 H.C. Wainwright reiterates Kymera Therapeutics stock rating at buy — 10/04/2026 [USA] Related: #Financial Analysis, #Investor Sentiment
• 🇺🇸 H.C. Wainwright reiterates Nurix stock rating, $32 target on catalysts — 10/04/2026 [USA] Related: #Financial Analysis, #Investments
• 🇺🇸 H.C. Wainwright reiterates Oncolytics Biotech stock rating at buy — 10/04/2026 [USA] Related: #Financial Analysis, #Investing
• 🇺🇸 H.C. Wainwright reiterates Invivyd stock rating on measles program — 10/04/2026 [USA] Related: #Financial Analysis, #Healthcare Investment
• 🇺🇸 Mizuho initiates Grail stock coverage with neutral rating on MCED outlook — 10/04/2026 [USA] Related: #Financial Analysis, #Healthcare Innovation
• 🇺🇸 Jefferies initiates Allogene stock coverage with buy rating on cancer therapy potential — 10/04/2026 [USA] Related: #Financial Markets, #Healthcare Innovation